2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121301
    Amperozide 75558-90-6 98.75%
    Amperozide is an atypical antipsychotic that acts as an antagonist of the 5-HT2 receptor with a Ki value of 26 nM. Amperozide has a low affinity for D2 receptors.
    Amperozide
  • HY-121392
    GR 125743 148547-33-5 99.77%
    GR 125743 is a selective 5-HT1B/1D receptor antagonist, with pKis of 8.85 and 8.31 for wild-type h5-HT1B and wild-type h5-HT1D, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases.
    GR 125743
  • HY-121537
    CAY10404 340267-36-9 ≥99.0%
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities.
    CAY10404
  • HY-121675
    2-Bromo-LSD 478-84-2
    2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation.
    2-Bromo-LSD
  • HY-121872
    DP-b99 222315-88-0
    DP-b99 is a chelator of zinc and calcium ions that acts selectively within cell membranes and has neuroprotective properties in animal models of stroke.
    DP-b99
  • HY-122255
    LY487379 353231-17-1 98.92%
    LY487379 is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 potentiates glutamate-stimulated [35S]GTPγS binding with EC50 values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 can be used for schizophrenia research.
    LY487379
  • HY-122376
    S-Bioallethrin 28434-00-6 98.16%
    S-Bioallethrin (D-Trans-Allethrin) is a pyrethroid insecticide. S-Bioallethrin disrupts nerve function by modifying the gating kinetics of transitions between the conducting and nonconducting states of voltage-gated sodium channels. S-Bioallethrin also causes inhibition of lymphocyte proliferation and induces histamine release from human basophils.
    S-Bioallethrin
  • HY-123495
    CRANAD-28 1623747-97-6 98.03%
    CRANAD-28 is a robust fluorescent compound for visualization of amyloid beta plaques.
    CRANAD-28
  • HY-12388A
    N-Desmethyl clomipramine hydrochloride 29854-14-6 99.95%
    N-Desmethyl Clomipramine hydrochloride (Desmethylclomipramine hydrochloride) is a primary plasma N-desmethyl metabolite of Clomipramine. Clomipramine is a tricyclic antidepressant.
    N-Desmethyl clomipramine hydrochloride
  • HY-123966
    MY33-3 2204280-41-9 98.84%
    MY33-3 is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction.
    MY33-3
  • HY-124424
    VU0071063 333415-38-6 99.71%
    VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC50=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships.
    VU0071063
  • HY-124543
    MRS-1191 185222-90-6 99.22%
    MRS-1191 is a potent and selective A3 adenosine receptor antagonist with a KB value of 92 nM, a Ki value of 31.4 nM for human A3 receptor and an IC50 of 120 nM for CHO cells. MRS-1191 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRS-1191
  • HY-124673
    AF40431 181125-92-8 98.09%
    AF40431, the first reported small-molecule ligand of sortilin, has an IC50 of 4.4 µM and a Kd of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.
    AF40431
  • HY-125287
    (Rac)-Minzasolmin 1802518-63-3 99.87%
    (Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease.
    (Rac)-Minzasolmin
  • HY-127109
    Tisolagiline 1894207-44-3 99.97%
    Tisolagiline (KDS2010) is the selective, reversible and orally active inhibitor for MAO-B with an IC50 of 8 nM. Tisolagiline exhibits neuroprotective and anti-neuroinflammatory activities.
    Tisolagiline
  • HY-12766S
    Bupropion morpholinol-d6 1216893-18-3 99.28%
    Bupropion morpholinol-d6 is the deuterated form of Bupropion morpholinol. Bupropion morpholinol is a major metabolite of Bupropion. Bupropion morpholinol inhibits Dopamine, Norepinephrine transporters and the α4β2 nicotinic receptor in vitro. Bupropion morpholinol contributes to antidepressant and smoking cessation activities.
    Bupropion morpholinol-d6
  • HY-128733
    Phenyl acetate 122-79-2 99.68%
    Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
    Phenyl acetate
  • HY-128855
    Talsaclidine 147025-53-4 ≥98.0%
    Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes. Talsaclidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Talsaclidine
  • HY-128865
    BPR1M97 2059904-66-2 98.32%
    BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects.
    BPR1M97
  • HY-128975
    m-Tyramine hydrobromide 38449-59-1 98.50%
    m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the adrenergic and dopaminergic receptor[1, 2].
    m-Tyramine hydrobromide
Cat. No. Product Name / Synonyms Application Reactivity